Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 694 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Mobilization Clear all
Completed Phase 2 Interventional Results available

S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis

NCT00064337
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Myeloma
Interventions
filgrastim, cyclophosphamide, dexamethasone, melphalan, thalidomide, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
35
States / cities
Little Rock, Arkansas • Sacramento, California • Boise, Idaho + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 24, 2026, 2:10 AM EDT
Terminated Phase 1 Interventional

Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)

NCT03396575
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma
Interventions
TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Cyclophosphamide + Fludarabine Lymphodepletive Conditioning, Dose-Intensified TMZ, Td vaccine, Autologous Hematopoietic Stem Cells (HSC)
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
3 Years to 30 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 24, 2026, 2:10 AM EDT
Completed Phase 1 Interventional

Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)

NCT05618301
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Motixafortide, Natalizumab, Leukapheresis
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 24, 2026, 2:10 AM EDT
Completed Phase 2 Interventional

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances

NCT00353860
View directory record Official record
Conditions
Immunosuppression, Leukemia
Interventions
SOLEX 300i Stem Cell Selection
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 24, 2026, 2:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of the Close to Home Program in California

NCT05206994
View directory record Official record
Conditions
Sexual Violence, Sexual Assault, Adolescent Behavior
Interventions
Close to Home
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
14 Years to 24 Years
Enrollment
953 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 24, 2026, 2:10 AM EDT
Completed Not applicable Interventional Results available

Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

NCT01383759
View directory record Official record
Conditions
Light Chain Deposition Disease (LCDD or MIDD), Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD), Monoclonal Immunoglobulin Deposition Disease (MIDD), Amyloidosis
Interventions
Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 24, 2026, 2:10 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Lumbosacral Joint Mobilization/Manipulation on Lower Extremity Muscle Neuromuscular Response

NCT00601341
View directory record Official record
Conditions
Knee Pain, Hip Pain, Ankle Pain, Lumbopelvic Pain
Interventions
lumbosacral joint manipulation, lumbar passive range of motion, No active intervention
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 50 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2010 · Synced Oct 24, 2026, 2:10 AM EDT
Enrolling by invitation Phase 4 Interventional

Prospective Opioid-Free AIS Fusion

NCT06935331
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis (AIS)
Interventions
Opioid-Free/Opioid-Avoidant, Opioid-Containing
Drug
Lead sponsor
OrthoCarolina Research Institute, Inc.
Other
Eligibility
10 Years to 20 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 24, 2026, 2:10 AM EDT
Terminated Not applicable Interventional

Influence of Opioid Use on the Effects of Spinal Manipulative Therapy for Low Back Pain

NCT03749564
View directory record Official record
Conditions
Low Back Pain, Opioid Use
Interventions
SMT, Activation Exercises, Mobilizing Exercises, Extended SMT
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 24, 2026, 2:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT02227199
View directory record Official record
Conditions
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Carboplatin, Etoposide, Ifosfamide, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 24, 2026, 2:10 AM EDT
Completed Phase 2 Interventional Results available

Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients

NCT00322387
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Multiple Myeloma
Interventions
G-CSF and plerixafor
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
5
States / cities
Duarte, California • Beech Grove, Indiana • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 24, 2026, 2:10 AM EDT
Completed Phase 2 Interventional Results available

Optimization of Spinal Manipulative Therapy Protocols

NCT02868034
View directory record Official record
Conditions
Low Back Pain
Interventions
SMT, Mobilizing Exercises, Activation Exercises, SMT extended
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 60 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 24, 2026, 2:10 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

NCT04293185
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
bb1111
Genetic
Lead sponsor
Genetix Biotherapeutics Inc.
Industry
Eligibility
2 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 24, 2026, 2:10 AM EDT
Recruiting Phase 3 Interventional

D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM

NCT07624513
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS)
Drug · Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 24, 2026, 2:10 AM EDT
Terminated Phase 3 Interventional Results available

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

NCT00568633
View directory record Official record
Conditions
Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia (AML)
Interventions
Allogeneic HSCT, Anti-thymocyte globulin (ATG), Cyclosporine (CSP), Mycophenolate mofetil (MMF), Total lymphoid irradiation (TLI), Methylprednisolone sodium succinate, Best standard care
Procedure · Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
5
States / cities
Hayward, California • Los Angeles, California • Sacramento, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 24, 2026, 2:10 AM EDT
Completed Not applicable Interventional

Mobilizing Community Systems to Engage Families in Early Autism Spectrum Disorder (ASD) Detection & Services

NCT02445105
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Autism Navigator Enhanced Practice, Family Engagement plus Autism Navigator
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
Not listed
Enrollment
10,857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
4
States / cities
Tallahassee, Florida • Atlanta, Georgia • White Plains, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Oct 24, 2026, 2:10 AM EDT
Completed Not applicable Interventional

Mobilization Versus Manipulation for the Treatment of Cervicogenic Headaches

NCT03919630
View directory record Official record
Conditions
Cervicogenic Headache
Interventions
Thrust Mobilization, Non-Thrust Mobilizations
Other
Lead sponsor
Franklin Pierce University
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Havertown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 24, 2026, 2:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Preventing Opioid Overdose Mortality in the United States

NCT03924505
View directory record Official record
Conditions
Opioid Overdose
Interventions
Organize and Mobilize for Implementation Effectiveness, Dissemination
Other
Lead sponsor
RTI International
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 24, 2026, 2:10 AM EDT
Withdrawn Not applicable Interventional

Efficacy of Methods to Treat Multiple Gingival Recession Defects

NCT03124329
View directory record Official record
Conditions
Gingival Recession
Interventions
Coronally Advanced Flap, Intrasulcular Tunneling, Vestibular Incision Subperiosteal Tunnel Access (VISTA), Leukocyte-Platelet Rich Fibrin (L-PRF)
Procedure · Biological · Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 24, 2026, 2:10 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

NCT00074490
View directory record Official record
Conditions
Lymphoma, Leukemia, Myeloproliferative Disorders, Multiple Myleoma, Myelodysplastic Syndrome
Interventions
Rituximab, Fludarabine, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Peripheral blood stem cell (PBSC) transplantation, T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells, Prednisone, Allogeneic hematopoietic stem cell transplant (HSCT), Filgrastim, T-Rapa cell Donor Lymphocyte Infusion (DLI)
Drug · Procedure · Genetic
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
11 Years to 90 Years
Enrollment
442 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2017
U.S. locations
2
States / cities
Bethesda, Maryland • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 24, 2026, 2:10 AM EDT
Recruiting Not applicable Interventional

Robotic Rehabilitation of the Upper Limb in Subacute Stroke

NCT06839482
View directory record Official record
Conditions
Stroke
Interventions
Robotic Assisted Upper Limb Rehabilitation, Control Group (CG)
Device · Other
Lead sponsor
IRCCS San Raffaele Roma
Other
Eligibility
18 Years to 85 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Elkins Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 24, 2026, 2:10 AM EDT
Recruiting Not applicable Interventional

Normalizing Cervical Intersegmental Kinematics With Spinal Manipulative Therapy

NCT06312696
View directory record Official record
Conditions
Neck Pain
Interventions
SMT, Light Massage
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 39 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 24, 2026, 2:10 AM EDT
Enrolling by invitation No phase listed Observational

Influence of Flexion Distraction Manipulation on Measures of Performance and Postural Control

NCT06965920
View directory record Official record
Conditions
Spine Condition, Low Back Pain
Interventions
Not listed
Lead sponsor
Keiser University College of Chiropractic Medicine
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 24, 2026, 2:10 AM EDT
Completed Not applicable Interventional Results available

Pelvis RCT: Impact of Surgery on Pain in Lateral Compression Type Pelvic Fractures

NCT02625766
View directory record Official record
Conditions
LC Pelvic Fracture
Interventions
LC fracture surgical fixation, LC fracture non-operative management
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Indianapolis, Indiana • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 24, 2026, 2:10 AM EDT